Cylene pockets $44M in latest VC round
San Diego-based Cylene Pharmaceuticals has gained $44 million in its third round of venture funding. HBM BioVentures (Cayman) and Lilly Ventures led the round, which provides funds for the clinical advancement of small molecule cancer therapies. Much of that money will be used to pay for Phase II studies of CX-3543 in several different cancer indications and to advance two more products into development. CX-3543, Cylene's treatment of multiple cancers, acts as a Ribosomal RNA Biogenesis Inhibitor by targeting a Protein:DNA interaction that is amplified in cancer cells during Pol I transcription of the rRNA genes.
- here's the release on the venture round
Related Articles:
Cylene closes $26.3M round. Report
Biotech venture funding jumped in '06. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
